60690 Federal Register / Vol. 88, No. 170 / Tuesday, September 5, 2023 / Notices 

provide complete contact information 

for each attendee, including name, title, 

affiliation, address, email, and 

telephone. 

Registration is free and based on 

space availability, with priority given to 

early registrants. Early registration is 

recommended because seating is 

limited; therefore, FDA may limit the 

number of participants from each 

organization. Registrants will receive 

confirmation when they have been 

accepted. If time and space permit, 

onsite registration on the day of the 

public meeting will be provided 

beginning at 8 a.m. We will let 

registrants know if registration closes 

before the day of the public meeting. 

If you need special accommodations 

due to a disability, please contact Grace 

Carmouze-Cunningham (see FOR

FURTHER INFORMATION CONTACT) at least 7 

days before the meeting. 

Streaming Webcast of the Public 

Meeting: This public meeting will also 

be webcast. You will be asked to 

indicate in your registration if you plan 

to attend in person or via the webcast. 

Transcripts: Please be advised that as 

soon as a transcript of the public 

meeting is available, it will be accessible 

at https://www.regulations.gov. It may 

be viewed at the Dockets Management 

Staff (see ADDRESSES). A link to the 

transcript will also be available on the 

internet at https://www.fda.gov/ 

industry/fda-user-fee-programs/ 

prescription-drug-user-fee-amendments. 

Dated: August 29, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–19059 Filed 9–1–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–N–3549] 

Merck Sharp & Dohme LLC, et al.; 

Withdrawal of Approval of 35 New 

Drug Applications 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

withdrawing approval of 35 new drug 

applications (NDAs) from multiple 

applicants. The applicants notified the 

Agency in writing that the drug 

products were no longer marketed and 

requested that the approval of the 

applications be withdrawn. 

DATES: Approval is withdrawn as of 

October 5, 2023. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Lehrfeld, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 51, Rm. 6226, 

Silver Spring, MD 20993–0002, 301– 

796–3137, Kimberly.Lehrfeld@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

applicants listed in the table have 

informed FDA that these drug products 

are no longer marketed and have 

requested that FDA withdraw approval 

of the applications under the process in 

§ 314.150(c) (21 CFR 314.150(c)). The 

applicants have also, by their requests, 

waived their opportunity for a hearing. 

Withdrawal of approval of an 

application or abbreviated application 

under § 314.150(c) is without prejudice 

to refiling. 

Application No. Drug Applicant 

NDA 001546 ...... Guanidine (guanidine hydrochloride (HCl)) Tablets, 125 milligrams (mg).Merck Sharp & Dohme LLC, 126 East Lincoln Ave., P.O. Box 

2000, Rahway, NJ 07065. 

NDA 010841 ...... Peganone (ethotoin) Tablets, 250 mg and 500 mg ................. Recordati Rare Diseases Inc., 100 Corporate Dr., Lebanon, 

NJ 08833. 

NDA 016801 ...... Xylocaine Preservative Free (lidocaine HCl) Injection, 1%, 

2%, 4%, 10%, and 20%.

Fresenius Kabi USA, LLC, 3 Corporate Dr., Lake Zurich, IL 

60047. 

NDA 016822 ...... FreAmine 8.5% (amino acids) Injection, 8.5 grams (g)/100 

milliliters (mL).

B. Braun Medical Inc., 901 Marcon Blvd., Allentown, PA 

18109. 

FreAmine HBC 6.9% (amino acids) Injection, 6.9 g/100 mL.

FreAmine II 8.5% (amino acids) Injection, 8.5 g/100 mL.

FreAmine III 10% (amino acids) Injection, 10 g/100 mL.

FreAmine III 8.5% (amino acids) Injection, 8.5 g/100 mL.

FreAmine III 8.5% with electrolytes (amino acids, magnesium 

acetate, phosphoric acid, potassium acetate, potassium 

chloride, sodium acetate) Injection, 8.5%; 110mg/100mL; 

230mg/100mL; 10mg/100mL; 440mg/100mL; 690mg/ 

100mL.

FreAmine III 3% with electrolytes (amino acids, magnesium 

acetate, phosphoric acid, potassium chloride, sodium acetate, sodium chloride) Injection, 3%; 54mg/100mL; 40mg/ 

100mL; 150mg/100mL; 200mg/100mL; 120mg/100mL.

NDA 017407 ...... Catapres (clonidine HCl) Tablets, 0.1 mg, 0.2 mg, and 0.3 

mg.

Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury 

Rd., P.O. Box 368, Ridgefield, CT 06877. 

NDA 017425 ...... Proglycem (diazoxide) Capsules, 50 mg and 100 mg ............ Teva Branded Pharmaceutical Products R&D, Inc., 145 Brandywine Pkwy., West Chester, PA 19380. 

NDA 017534 ...... Fiorinal (aspirin, butalbital, caffeine) Capsules, 325 mg/50 

mg/40 mg.

AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 

60064. 

Fiorinal (aspirin, butalbital, caffeine) Tablets, 325 mg/50 mg/ 

40 mg.

NDA 018582 ...... Procalamine (amino acids, calcium acetate, glycerin, magnesium acetate, phosphoric acid, potassium chloride, sodium 

acetate, sodium chloride) Injection, 3%; 26mg/100mL; 3g/ 

100mL; 54mg/100mL; 41mg/100mL; 150mg/100mL; 

200mg/100mL; 120mg/100mL.

B. Braun Medical Inc. 

NDA 018676 ...... HepatAmine 8% (amino acids) Injection, 8g/100mL ............... Do. 

NDA 018878 ...... Indocin (indomethacin sodium) Injection, equivalent to (EQ) 1 

mg base/vial.

Recordati Rare Diseases Inc. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 170 / Tuesday, September 5, 2023 / Notices 60691 

Application No. Drug Applicant 

NDA 019099 ...... Dopamine HCl and Dextrose 5% Injection, 80 mg/100 mL 

and 320 mg/100 mL.

Dopamine HCl and Dextrose 5% in plastic container Injection, 40 mg/100 mL and 160 mg/100 mL.

B. Braun Medical Inc. 

NDA 019111 ...... Tussionex Pennkinetic (chlorpheniramine polistirex, 

hydrocodone polistirex) Extended-Release Suspension, EQ 

8 mg maleate/5 mL; EQ 10 mg bitartrate/5 mL.

UCB Inc., 1950 Lake Park Dr., Building 2100, Smyrna, GA 

30080. 

NDA 019429 ...... Fiorinal with Codeine (aspirin, butalbital, caffeine, codeine 

phosphate) Capsules, 325 mg/50 mg/40 mg/30 mg.

AbbVie Inc. 

NDA 019898 ...... Pravachol (pravastatin sodium) Tablets, 10 mg, 20 mg, 40 

mg, and 80 mg.

Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 

08543. 

NDA 020281 ...... Ultram (tramadol HCl) Tablets, 50 mg and 100 mg ................ Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton 

Rd., Titusville, NJ 08560. 

NDA 020381 ...... Niaspan (niacin) Extended-Release Tablets, 375 mg, 500 

mg, 750 mg, and 1 g.

AbbVie Inc. 

Niaspan Titration Starter Pack (niacin) Extended-Release 

Tablets, 375 mg, 500 mg, and 750 mg.

NDA 020544 ...... Jadelle (levonorgestrel) Implants for Subdermal Use, 75 mg/ 

implant.

Population Council, 1230 York Ave., New York, NY 10065. 

NDA 020616 ...... Kadian (morphine sulfate) Extended-Release Capsules, 10 

mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 

100 mg, 130 mg, 150 mg, and 200 mg.

AbbVie Inc. 

NDA 020636 ...... Viramune (nevirapine) Tablets, 200 mg .................................. Boehringer Ingelheim Pharmaceuticals, Inc. 

NDA 021065 ...... Femhrt (ethinyl estradiol, norethindrone acetate) Tablets, 

0.0025 mg/0.5 mg and 0.005 mg/1 mg.

Allergan Pharmaceuticals International Limited c/o AbbVie 

Inc., 1 North Waukegan Rd., North Chicago, IL 60064. 

NDA 021066 ...... Zaditor (ketotifen fumarate) Ophthalmic Solution, EQ 0.025% 

base.

Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, 

TX 76134. 

NDA 021123 ...... Ultracet (acetaminophen, tramadol HCl) Tablets, 325 mg/ 

37.5 mg.

Janssen Pharmaceuticals, Inc. 

NDA 021513 ...... Enablex (darifenacin hydrobromide) Extended-Release Tablets, EQ 7.5 mg base and EQ 15 mg base.AbbVie Inc. 

NDA 021615 ...... Razadyne ER (galantamine hydrobromide) Extended-Release Capsules, EQ 8 mg base, EQ 16 mg base, and EQ 

24 mg base.

Janssen Research and Development, LLC, 1125 TrentonHarbourton Rd., Titusville, NJ 08560. 

NDA 021790 ...... Dacogen (decitabine) Injection, 50 mg/vial .............................. Otsuka Pharmaceutical Co., Ltd., c/o Otsuka Pharmaceutical 

Development and Commercialization, Inc., 2440 Research 

Blvd., Rockville, MD 20850. 

NDA 021830 ...... Asacol HD (mesalamine) Delayed-Release Tablets, 800 mg AbbVie Inc. 

NDA 021844 ...... Desonate (desonide) Gel, 0.05% ............................................. LEO Pharma A/S, c/o LEO Pharma Inc., 7 Giralda Farms, 

Madison, NJ 07940. 

NDA 022292 ...... Aptivus (tipranavir) Oral Solution, 100 mg/mL ......................... Boehringer Ingelheim Pharmaceuticals, Inc. 

NDA 022439 ...... Zutripro (chlorpheniramine maleate, hydrocodone bitartrate, 

pseudoephedrine HCl) Oral Solution, 4 mg/5 mL; 5 mg/5 

mL; 60 mg/5 mL.

Persion Pharmaceuticals LLC, 10 North Park Place, Suite 

201, Morristown, NJ 07960. 

NDA 022442 ...... Rezira (hydrocodone bitartrate, pseudoephedrine HCl) Oral 

Solution, 5 mg/5 mL; 60 mg/5 mL.

Do. 

NDA 204307 ...... Vituz (chlorpheniramine maleate, hydrocodone bitartrate) 

Oral Solution, 4 mg/5 mL; 5 mg/5 mL.

Do. 

NDA 204768 ...... Tivorbex (indomethacin) Capsules, 20 mg and 40 mg ........... Genus Lifesciences Inc., 514 North 12th St., Allentown, PA 

18102. 

NDA 206619 ...... Viekira Pak (dasabuvir sodium; ombitasvir, paritaprevir, 

ritonavir) Tablets, EQ 250 mg base; 12.5 mg/75 mg/50 mg.

AbbVie Inc. 

NDA 208374 ...... Bivalirudin in 0.9% Sodium Chloride Intravenous Solution, 

250 mg/50 mL and 500 mg/100 mL.

Baxter Healthcare Corp., 1 Baxter Pkwy., Deerfield, IL 

60015. 

NDA 210583 ...... Anjeso (meloxicam) Intravenous Solution, 30 mg/mL ............. Baudax Bio, Inc., 490 Lapp Rd., Malvern, PA 19355. 

Therefore, approval of the 

applications listed in the table, and all 

amendments and supplements thereto, 

is hereby withdrawn as of October 5, 

2023. Approval of each entire 

application is withdrawn, including any 

strengths and dosage forms included in 

the application but inadvertently 

missing from the table. Introduction or 

delivery for introduction into interstate 

commerce of products listed in the table 

without approved new drug 

applications violates sections 505(a) and 

301(d) of the Federal Food, Drug, and 

Cosmetic Act (21 U.S.C. 355(a) and 

331(d)). Drug products that are listed in 

the table that are in inventory on 

October 5, 2023 may continue to be 

dispensed until the inventories have 

been depleted or the drug products have 

reached their expiration dates or 

otherwise become violative, whichever 

occurs first. 

Dated: August 29, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–19013 Filed 9–1–23; 8:45 am] 

BILLING CODE 4164–01–P 


ddrumheller on DSK120RN23PROD with NOTICES1